- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Boehringer Ingelheim
Ingelheim/Germany, 17 November 2008
Progress continues across expanding oncology pipeline with two compounds now in phase III clinical development and a potential first-in-class polo-like kinase 1 inhibitor soon to enter phase II.
Boehringer Ingelheim has marked a new milestone within its rapidly expanding oncology portfolio with the announcement today that the company has progressed another of its oncology compounds into pivotal phase III clinical development (LUME-Lung 1 and LUME-Lung 2). In addition, Boehringer Ingelheim’s most advanced compound BIBW 2992* will soon enter its second pivotal trial, LUX-Lung 3 in first-line NSCLC. Furthermore, a new compound and potentially first-in class-molecule, polo-like kinase 1 (Plk1) inhibitor, BI 6727*, has demonstrated such positive phase I results that it will be progressed to phase II.
*BIBF 1120, BIBW 2992 and BI 6727 are investigational compounds. Their safety and efficacy have not yet been fully established.
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
